Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 26, 2025, titled "Zydus and RK Pharma enter into an exclusive licensing and commercialization agreement for a novel 505(b)(2) product of supportive oncology treatment for the USA market.".
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Lifesciences has signed an exclusive licensing and commercialization agreement with RK Pharma for a novel 505(b)(2) product used in supportive oncology treatment. The 505(b)(2) pathway is an FDA route that allows companies to bring new formulations or combinations of existing drugs to market faster. The product will be targeted at the US market. Under the deal, Zydus will likely handle the commercialization while RK Pharma contributes the product. This adds a new specialty product to Zydus' growing US oncology and supportive care portfolio. The agreement strengthens Zydus' footprint in the US generics and specialty pharmaceutical space.
Positive for Zydus shareholders — the deal expands the company's US product pipeline and opens an additional revenue stream in oncology supportive care, though near-term financial impact will depend on launch timelines and market uptake.